A5072715491- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Diabetes Management and Research
- Pharmacology and Obesity Treatment
- Diet and metabolism studies
- Pancreatic function and diabetes
- Liver Disease Diagnosis and Treatment
- Medication Adherence and Compliance
- Diabetes and associated disorders
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical studies and practices
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Gastric Cancer Management and Outcomes
- Folate and B Vitamins Research
- Body Composition Measurement Techniques
- Pharmaceutical Practices and Patient Outcomes
- Thermoregulation and physiological responses
- Nutrition and Health in Aging
- Chronic Lymphocytic Leukemia Research
- Cardiovascular Disease and Adiposity
- Cardiovascular Function and Risk Factors
- Diabetes Management and Education
- Regulation of Appetite and Obesity
- Advanced MRI Techniques and Applications
- Growth Hormone and Insulin-like Growth Factors
Eli Lilly (United States)
2014-2024
Indianapolis Zoo
2021-2022
Age UK
2022
Wilmington University
2018
Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno
2009
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that under development for the treatment of type 2 diabetes. The efficacy safety once-weekly tirzepatide as compared with semaglutide, selective GLP-1 agonist, are unknown.
Importance Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist used for the treatment of type 2 diabetes. Efficacy safety adding tirzepatide vs prandial insulin to in patients with inadequate glycemic control basal have not been described. Objective To assess efficacy lispro as an adjunctive therapy glargine. Design, Setting, Participants This open-label, phase 3b clinical trial was conducted at 135 sites 15 countries (participants...
Aims To compare adherence (proportion of days covered [ PDC ]), persistence, and treatment patterns among patients with type 2 diabetes mellitus ( T2DM ) newly initiating glucagon‐like peptide‐1 receptor agonists GLP‐1RAs ). More specifically, the main objectives were to dulaglutide vs exenatide once weekly liraglutide. Methods Patients dulaglutide, albiglutide, weekly, twice daily liraglutide between N ovember 2014 A pril 2015 hierarchically selected from T ruven H ealth's MarketScan R...
Abstract Background Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide/ glucagon-like peptide-1 receptor agonist, is approved in the United States, Europe and Japan for treatment of type 2 diabetes. Across SURPASS-1 to -5 clinical studies, tirzepatide 5, 10 15 mg demonstrated significant improvements glycated haemoglobin A1c (HbA1c) (− 1.9 − 2.6%), body weight 6.6 13.9%) systolic blood pressure (SBP) 2.8 12.6 mmHg) at end study treatment. Methods Post-hoc mediation...
Tirzepatide is a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for treatment of type 2 diabetes (T2D). SURPASS-1, phase 3 trial tirzepatide monotherapy in people with early T2D, enables evaluating effects on pancreatic beta-cell function insulin sensitivity (IS) without other background antihyperglycemic medications.
Aims To evaluate adherence, persistence, glycaemic control and costs at 12‐month follow‐up for patients initiating dulaglutide versus liraglutide or exenatide once weekly. Materials methods The present retrospective observational claims study included with type 2 diabetes (T2D) ≥ 1 pharmacy claim dulaglutide, weekly from the HealthCore Integrated Research Database. Adherence was defined as proportion of days covered ≥80%, persistence measured by time to discontinuation index therapy. Change...
OBJECTIVE Tirzepatide is a novel single-molecule glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, which demonstrated unprecedented improvements in glycemic control and body weight reduction, the SURPASS phase 3 program. In this exploratory analysis, we aimed to characterize tirzepatide-treated participants who achieved HbA1c <5.7% evaluate changes clinical markers associated with long-term cardiometabolic health. RESEARCH DESIGN AND METHODS...
Abstract Aims To describe the overall fat distribution patterns independent of body mass index (BMI) in participants with type 2 diabetes (T2D) SURPASS‐3 MRI substudy by comparison sex‐ and BMI‐matched virtual control groups (VCGs) derived from UK Biobank imaging study at baseline Week 52. Methods For each participant 52 ( N = 296), a VCG ≥150 same sex similar BMI was identified 40 172). Average visceral adipose tissue (VAT), abdominal subcutaneous (aSAT) liver (LF) levels observed standard...
To assess glycemic effectiveness, adherence and persistence within 6 months of treatment initiation with dulaglutide, a once weekly GLP-1 receptor agonist, in US real-world setting.This retrospective claims analysis included adults (≥18 years) T2DM from the HealthCore Integrated Research Database, who had HbA1c laboratory results around after initiation. Glycemic control was assessed by change pre-initiation to post-initiation. Patients were considered adherent if their proportion days...
Abstract Aim To assess the relationship between HbA1c and body weight reductions with tirzepatide treatment (5, 10 or 15 mg). Materials Methods data at 40 weeks (SURPASS‐1, ‐2 ‐5) 52 (SURPASS‐3 ‐4) were analysed by trial. Results Across SURPASS clinical trials, from baseline observed in 96%‐99%, 98%‐99% 94%‐99% of participants treated 5, mg, respectively. Moreover, 87%‐94%, 88%‐95% 88%‐97% participants, respectively, experienced loss associated reductions. Statistically significant...
Tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist, is approved for glycaemic control people with type 2 diabetes (T2D). The SURPASS-1 to -5 clinical trials assessed the efficacy of once weekly tirzepatide (5, 10 15 mg) versus placebo or active comparators (semaglutide mg, insulin degludec glargine) in T2D. We evaluated patient-reported outcomes (PROs) that measured overall quality life (QoL), treatment satisfaction weight-related...
To assess the relationship between weight change and glycated haemoglobin (HbA1c) in dulaglutide-treated patients by analysing data from six head-to-head phase III AWARD clinical trials.At 26 weeks, HbA1c was analysed each trial rather than pooling because of differences design background therapy. The effect baseline characteristics also evaluated with regard to response.Across studies, 87-97% 83-95% treated dulaglutide 1.5 0.75 mg, respectively, had reductions levels, while 57-88% 43-84%...
Qualitative exit interviews can supplement clinical trial results by providing a rich and detailed picture of the patient's experience, while highlighting treatment benefits that are meaningful to patients. Exit be particularly useful for insight into newer medications when less is known about subjective experience treatment. Tirzepatide novel dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) receptor agonist type 2 diabetes mellitus. The purpose this...
Liraglutide and dulaglutide have demonstrated similar glycemic efficacy safety. However, they differ in treatment administration injection devices. The purpose of this study was to examine compare patient perceptions the devices used with liraglutide dulaglutide.Patients type 2 diabetes treated or were recruited from across US. Patients completed Diabetes Injection Device Experience Questionnaire (DID-EQ) rate their current device. who had experience both treatments also Preference (DID-PQ)...
To assess efficacy and safety of dulaglutide 1.5 mg combined with insulin, categorized by subgroups baseline glycated haemoglobin (HbA1c; ≤9% >9% [≤74.9 >74.9 mmol/mol]), age (<65 ≥65 years), duration diabetes (<10 ≥10 years) at 6 months in patients type 2 (T2D).This pooled analysis was conducted a population T2D similar characteristics who were included the AWARD-4 AWARD-9 clinical trials randomized to (pooled mean 59 years, 13 HbA1c 8.4% [68.3 mmol/mol]). Weight hypoglycaemia analysed...